Cite this article as: Guerrera F, Renaud S, Tabb o F, Voegeli' A-C, Filosso PL, Legrain M et al. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. Eur J Cardiothorac Surg 2017;51:680-8. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas † Abstract OBJECTIVES: The impact of skip N2 metastases (i.e. N2 lymph node metastases without N1) on survival in surgically resected non-small lung cancer remains an intriguing and rarely investigated topic. The goal of our study was to elucidate (i) skip N2 influence on overall survival (OS) and time to recurrence (TTR) in patients with resected lung adenocarcinoma and (ii) its link with epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations.
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality worldwide. In this context, the eighth edition of the TNM classification for non-small-cell lung cancer (NSCLC) will be published in late 2016 and enacted in January 2017 [1] . However, in clinical practice, even patients with the same stage may present wide variations of survival and tumour relapse.
Among TNM parameters, the nodal component (N) remains of particular interest due to its importance in indicating prognosis and in tailoring the optimal therapeutic protocol. Particularly, the data in the eighth edition of the TNM showed that prognosis of N1 and N2 involvement could change according to the number of metastatic lymph node stations [2] . As matter of fact, N2 NSCLC disease represents a surprisingly heterogeneous group of patients: numerous papers demonstrated different outcomes according to the different number of lymph nodal stations involved (uni-versus multistation), the lymph node ratio or the presence of microscopic N2 disease [3] [4] [5] [6] .
Moreover, several previously published studies indicated that patients with pathologically proved mediastinal lymph node involvement (i.e. pN2) in the absence of intrapulmonary or hilar lymph node disease (skip N2) benefit from an improved survival rate [7] . Different hypotheses were proposed to explain mechanisms underlying the skip N2 pathway of lymph node metastasis, ranging from the pure anatomical reason [8] to the preferential drainage through the lymphatic vessels of the parietal pleura [9] . Indeed, skip N2 individuals represent a unique population among lung cancer patients, but the essential reasons for their better biological behaviour remain unclear.
In past years, there was a growing interest in the molecular alterations in NSCLC. The most frequent genomic mutations observed in lung adenocarcinoma were the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene, which was observed in 20-35% of patients, and the epidermal growth factor receptor (EGFR) mutations, which occurred in 10-20% of White patients [10] . The published results concerning driving mutations with a prognostic value in resected NSCLC were conflicting. A recent meta-analysis showed that a lack of EGFR mutations impact survival and disease-free survival in patients with surgically resected NSCLC [11] . However, only 6 of the 22 studies included were based on non-Asian cohorts, and the observed rates of EGFR mutations were >25% in 14/22 studies. Consequentially the results presented were unlikely applicable in White patients, in whom the frequency of EGFR mutations approaches 10%. Nevertheless, two recently published studies documented a reduced survival rate in surgically resected patients with the KRAS mutation, whereas EGFR mutations were associated with a favourable prognosis [12, 13] . Therefore, our aim was to explore outcomes, clinicopathological characteristics and the most important driving mutations of skip N2 adenocarcinomas of the lung in a cohort of 279 surgically treated European patients.
METHODS

Patient cohort and clinicopathological features
This study was approved by the ethics committees of Azienda Ospedaliera Universitaria Citt a della Salute e della Scienza di Torino (Protocol number: 0081521) and of the French Society of Thoracic and Cardiovascular Surgeons (Approval Number: CERC-SFCTCV-2016-2-26-9-34-26-ReSt) From 2003 to 2013, patients who underwent surgical resection with curative intent for lung adenocarcinoma at Azienda Ospedaliera Universitaria Citt a della Salute e della Scienza di Torino (Turin, Italy) and Strasbourg University Hospital (Strasbourg, France) were retrospectively reviewed.
All included patients harboured pathologically proven N2 involvement. N1 and N2 stations were determined according to the IASLC lymph nodal map [14] . Skip N2 metastases were defined as the presence of metastases in N2 lymph nodes in the absence of metastatic involvement of N1 lymph nodes, as previously published [7] .
Patients treated with preoperative protocols (i.e. chemotherapy, radiotherapy) were included. Multimodality treatment was discussed by the multidisciplinary board in the presence of a certified thoracic surgeon, a medical-and a radiation-oncologist. Patients were referred to our departments by various oncologists from different centres; consequently, no strict protocol and indications for induction treatment were performed. However, induction treatment was usually offered to patients with resectable tumours preoperatively classified as cN2 or with tumours not immediately resectable.
The preoperative assessment of each patient included standard chest radiographs; thoracic-, brain-and upper-abdominal computed tomography (CT) scans; whole-body 18-fluorodeoxyglucose positron emission tomography (PET) scans in recent years; fibre-optic bronchoscopy; electrocardiograms; and lung function tests. When N2 involvement was suspected from the preoperative images in patients with resectable tumours, histological proof was obtained by fibreoptic transbronchial needle aspiration, endobronchial ultrasonography and/or mediastinoscopy. Perfusion lung scanning and echocardiography were requested in case of a planned major surgical procedure. If induction treatment was administered, thoracic-, brain-and upper-abdominal CT scans and a PET scan (in recent years) were performed to evaluate the response to treatment and to exclude progression of disease.
The clinicopathological parameters for the studies included age; gender; smoking behaviour; type of surgical resection (e.g. lobectomy, bilobectomy, pneumonectomy, segmentectomy/ wedge resection); presence of vascular invasion; pT staging (all tumours were classified according to the seventh edition of the TNM classification for lung cancer); N2 multistation; number of harvested lymph nodes; resection status (i.e. R0/R1/R2); and preoperative and postoperative treatment. Appropriate anatomical resections and systematic nodal dissections were accomplished according to the recommendations of the European Society of Thoracic Surgeons and the French Society of Thoracic and Cardiovascular Surgeons [15, 16] . Moreover, after surgery, the pathologist performed an additional dissection to evaluate 10, 11 and 12 lymph-node stations. Physicians referred patients to our facilities from different centres. Therefore, no uniform protocol of preoperative or adjuvant therapy was used. Surgery was defined as radical (R0) when a complete tumour resection was accomplished, and incomplete in case of microscopically (R1) or macroscopically (R2) residual disease.
Genomic deoxyribonucleic acid extraction and hot-spot mutation
The specimens analysed consisted of formalin-fixed paraffinembedded blocks, archived as part of the respective institutional biobanks [17] . Molecular analysis was performed as previously published [13, 17] . Data concerning EGFR and KRAS hot-spot mutations were collected: exons 18-21 for EGFR and exon 2 codon 12/13 for KRAS were evaluated.
Statistical analyses
Categorical data are presented as a number (percentage, %) and continuous data as the median (interquartile range) or as the mean with standard deviation.
Associations between skip N2 metastasis, clinicopathological characteristics and EGFR/KRAS mutations were investigated with the use of the Mann-Whitney U-test for continuous variables and the v 2 test, Fisher's exact test and Cramé r's V-test for categorical variables, when appropriate [18] .
The overall survival (OS), as shown with the Kaplan-Meier method/curves, was defined as the time from the date of the intervention to the date of death by any cause; patients still alive on the date of the last follow-up were censored. The time to recurrence (TTR) was defined as the time from the date of intervention to the date of local or distant tumour relapse. TTR was assessed in R0 patients only.
A Cox proportional hazard model with shared frailty (accounting for the within-centre correlation) was used to estimate the crude and adjusted hazard ratios (HRs) and 95% confidence interval (CI) and to evaluate possible predictors of OS and TTR. Follow-up duration was used as the time scale; year of surgical intervention was introduced as the categorical variable (not shown in the models). Predictors of OS and TTR associated with P < _ 0.2 on univariable analysis were included in the multivariable model. All of the tests were two-sided, and variables were considered significant for P-values <0.05.
Statistical analyses were performed using Stata 13.1 (StataCorp LP, College Station, TX, USA).
RESULTS
According to the selection criteria, 279 patients with lung adenocarcinoma were included in the analyses. The clinicopathological characteristics of these patients are shown in Table 1 . Most of the patients were men (60%) and smokers (73%). The mean age at time of surgery was 63 years (SD ±12). The median follow-up time was 36 months (min 3; max 101).
Hot-spot mutations were evaluated in 261 patients (94%): EGFR mutations were observed in 38 patients (14%), whereas 86 patients had KRAS mutations (31%). Analyses of the EGFR mutations showed 18 (47%) exon 19 deletions, 3 (8%) exon 20 mutations, 16 (42%) exon 21 mutations and 1 (3%) exon 19 deletion plus exon 20 mutations. Analyses of KRAS codon 12 transversions revealed 65 (76%) G12C, 6 (7%) G12V and 3 (3%) G12A. Analyses of KRAS codon 12 transitions revealed 4 (5%) G12D and 1 (1%) G12S. Four KRAS codon 13, 4 (5%) G13C transversions and 3 (3%) G13D transitions were observed. All of these mutations were mutually exclusive from one another.
Clinicopathological variables and skip N2 Table 1 shows the distribution of clinicopathological variables according to the presence of skip N2. Skip N2 was observed in 54 patients (19%). Patients with skip N2 metastasis were predominantly non-smokers (P = 0.001), underwent segmentectomy or limited resection (P = 0.004) and more rarely had adjuvant therapy (P = 0.022). No difference between skip-and not-skip N2 was observed in regard to age, gender, pT stage, N2 multistation, number of harvested lymph nodes, vascular invasion and preoperative treatment submission.
There was a correlation between EGFR mutations and skip N2 (Cramé r's V: 0.25, degree of freedom: 1, P < 0.001). Indeed, EGFR mutations were significantly more frequent in skip N2 tumours (33%) than in not-skip (10%), P < 0.001. The power for association between the EGFR mutation and the skip N2 criteria was tested using 100 000 bootstrap replications: Power was estimated at 91% over all replications. No correlation between skip N2 and KRAS mutations was observed (Cramé r's V: 0.05, degree of freedom: 1, P = 0.46).
Survival analyses
One hundred and thirty-three patients (48%) were reported to be alive and 146 (52%) died during the follow-up period. Overall, the 5-year survival rate was 44% (Fig. 1) . We did not observe any significant difference in survival rates by skip N2 (5-year survival rate: 42%) and not-skip N2 (5-year survival rate: 44%; P = 0.84; Fig. 2) .
Results of univariable and multivariable Cox models for survival are shown in Table 2 . In univariable analysis, age (HR 1.028; P< 0.001; 95% CI 1.012-1.044), pT stage (pT2 HR 1.745, P = 0.018, 95% CI 1.1-2.767; pT3 HR 2.11, P = 0.005, 95% CI 1.253-3.553; pT4 HR 2.517, P = 0.001, 95% CI 1.395-4.54), presence of vascular invasion (HR 2.138; P < 0.001; 95% CI 1.454-3.143) and segmentectomy/wedge surgical resection (HR 1.713; P = 0.037; 95% CI 1.0342-2.838) were found to have a negative effect on survival. Adjuvant treatment showed a benefit on survival (chemotherapy alone, HR 0.304; P< 0.001; 95% CI 0.169-0.546; chemotherapy + radiotherapy HR 0.339; P< 0.001; 95% CI 0.188-0.611). Though non-significant but approaching significance, skip N2 was associated with a better OS (HR 0.656; P = 0.063; 95% CI 0.421-1.023). EGFR and KRAS mutational status was not a significant predictor on univariable analysis.
The multivariable-adjusted model showed a skip N2 independent protective effect on OS (HR 0.503; P = 0.014; 95% CI 0.291-0.870). Adjuvant treatment demonstrated an independent benefit on survival (chemotherapy alone HR 0.416; P = 0.006; 95% CI 0.224-0.774; chemotherapy + radiotherapy HR 0.44; P = 0.014; 95% CI 0.228-0.848). Furthermore, pT stage (pT2 HR 2.139, P = 0.01, 95% CI 1.203-3.802; pT3 HR 2.688, P = 0.004, 95% CI 1.38-5.236; pT4 HR 3.306, P = 0.002, 95% CI 1.573-6.948), presence of vascular invasion (HR 1.968; P = 0.005; 95% CI 1.222-3.169) and segmentectomy/wedge surgical resection (HR 4.849; P< 0.001; 95% CI 2.329-10.096) were independent negative predictors of survival.
Analyses of time to recurrence
In total, 249 R0 patients were available for the TTR analysis: 132 patients (51%) had a tumour recurrence during the follow-up period. Overall, the 5-year TTR rate was 0.67 (Fig. 3) . Recurrence rates with skip N2 showed a lower 5-year TTR rate for skip N2 (0.45) vs not skip N2 (0.71; P = 0.09; Fig. 4) . Moreover, 5-year TTR rates in patients with EGFR hot-spot mutations were lower (5-year TTR: 0.48 vs 0.69; P = 0.12; Fig. 5 ).
Results of univariable and multivariable Cox models for TTR are shown in the Supplementary Material, Table S1 .
No prognostic factors were significant in univariable analyses. However, there was a trend towards improved TTR in skip N2 (HR 0.608; P = 0.071).
On multivariable analysis, only adjuvant radiotherapy demonstrated an independent negative effect on TTR (HR 5.138; P = 0.019; 95% CI 1.312-20.116).
DISCUSSION
The primary objective of our study was to elucidate the influence of skip N2 on OS and TTR in patients with surgically resected lung adenocarcinoma. Moreover, we aimed to define the mutation profile of skip N2 tumours (i.e. EGFR and KRAS hot-spot mutations). The results of our study showed that (i) skip N2 demonstrated an independent protective effect on OS and (ii) a longer TTR; moreover, (iii) EGFR mutations were significantly more frequent in skip N2 tumours (especially in case of exon 20 mutations).
A better survival rate in skip N2 patients with surgically resected NSCLC was reported in several studies, but the reason for the nodal station 'jump' remains an intriguing and rarely investigated topic. In our series of patients with lung adenocarcinoma, the incidence of skip N2 metastasis was lower than the majority of rates reported in literature [7, [19] [20] [21] . However, several studies conducted on White cohorts indicated a higher skip N2 occurrence in patients with squamous cell carcinoma than in those with adenocarcinoma [20, 21] . In this study, we did not find a significant benefit in 5-year OS with skip N2; however, we did find an independent protective effect of skip N2 in multivariable analysis of survival. Indeed, even non-significant (but very close) skip N2 was associated with a better OS using the Cox univariable model (P = 0.063; 95% CI 0.421-1.023). Significance probably was not reached using univariable analysis because of the relatively low number of skip N2 patients (n = 54), which magnifies possible confounding factors. Actually, in our series, skip N2 patients more frequently underwent limited surgical resections and were more rarely submitted to adjuvant therapy, both independent prognostic factors in our analysis. Consequentially, a possible explanation could be the survival advantage in non-skip N2 patients provided by the major anatomical resection and adjuvant regimens. Nevertheless, our results confirmed better outcomes in terms of survival and tumour recurrence in patients with skip N2 adenocarcinoma. These findings were in line with previously published results [7, [19] [20] [21] . The favourable prognostic values of EGFR mutations in advanced-stage lung adenocarcinoma are clearly established in recent publications [10] . Furthermore, several papers documented a better prognosis based on surgical stages [12, 22, 23] . However, it is possible to wonder whether the benefit reported in the previous studies of EGFR mutations could be partially attributable to tyrosine-kinase inhibitors, systematically administrated to treat recurrence. So far, it is not possible to answer this question from the published data because existing results on disease-free survival patients with EGFR mutations and surgical resection are conflicting. In our series, we could not identify an influence of EGFR mutations on OS; we noted only an advantage on TTR (Fig. 5) . However, our population was highly selected, probably leading to an inclusion bias, preventing a conclusion about the prognostic value of EGFR mutations.
More notably, we reported a high incidence of EGFR mutations in skip N2 tumours. To the best of our knowledge, this is the first investigation that brings to light an association between EGFR mutations and skip N2 metastases. Recently, Li et al. [19] analysed an Asiatic cohort of 177 N2-patients without proving a correlation between hot-spot mutations (EGFR and KRAS) and the skip N2 pattern. However, the rate of EGFR mutations (53%) was remarkably higher than in the present study (14%); therefore, the result of Li et al. is probably not applicable to a White population. Consequently, whether skip N2 presents a different prognosis and a more favourable disease progression because of the higher incidence of EGFR mutations remains an open question. The possible influence of EGFR mutations on the mechanisms underlying the skip N2 pathway of lymph nodal metastasis is also unclear.
The easiest hypothesis could be based on Stephen Paget's original 'seed and soil' theory [24] : the 'skip' of the N1 lymph nodal stations and the colonization of the mediastinal stations might be the product of a complex interaction between EGFR-mutated adenocarcinoma (the 'seed') and microenvironment of the mediastinal lymph nodes (the 'soil'). The N2 microenvironment is probably different from the hilar and the intraparenchymal microenvironments and is more prone to be seeded by EGFRmutated cells.
Moreover, as documented by Zielinski et al. [25] , in the regional lymph nodes of patients with NSCLC, immune cells demonstrated a microenvironmental pattern that changed according to the distance from the primary tumour. Their results indicated that, in proximal lymph nodes, the tumour induced a lack of immune cells potentially capable of killing tumour cells and of creating an environment supporting lymph node cancer involvement. Hypothetically, in lung adenocarcinomas with EGFR mutations, the skip N2 phenomenon could represent the end product of a different capacity of the tumour to influence the nearby lymph node microenvironment. Consequentially, in this type of tumour, the pattern of the metastases to the lymph nodes was not proximity-driven and nearer lymph nodes did not offer a Time to recurrence according to N2 Skip favourable habitat as in other cases. One possible explanation could be the unique finding of the EGFR exon 20 mutation in skip N2 tumours: probably, different kinds of mutations could activate different downstream signalling pathways, inducing different microenvironment changes and diverse metastatic behaviours. However, the limited number available for our study did not allow us to make a definitive statement. This hypothesis should be elucidated by further investigations. A recent report suggested that primary NSCLC and lymphnode N2 metastases had stable EGFR mutations and, contrariwise, c-Met gene amplification was significantly higher in N2 metastatic lymph nodes than in primary tumours [26] . The change of genetic landscape in the lymph nodes, including the metastasis dissemination process, could explain the first 'jump' of N1 lymph nodes and the subsequent establishment of tumour cells in mediastinal nodal stations.
However, our study has some limitations that should be taken into account when analysing the results. It is a retrospective cohort study based on a relatively small sample size.
In conclusion, in our series, lung adenocarcinoma with skip N2 metastases had a favourable prognosis. The presence of EGFR mutations could have significance in the better survival and in the specific anatomic pathway of lymphatic metastases observed with skip N2 tumours. However, our results must be interpreted with caution because of the limitations listed above. More studies on larger cohorts are necessary to confirm these preliminary results.
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